Calithera Biosciences

Tumor metabolism and tumor immunology have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients.

Our lead product candidate in tumor metabolism, CB-839, is an internally discovered, first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism. We are currently evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors.

In tumor immunology, our lead preclinical program is directed at developing inhibitors of the enzyme arginase and may provide a first-in-class therapeutic agent for this novel target. Our ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets.

Company Growth (employees)
Type
Public
HQ
South San Francisco, US
Founded
2010
Size (employees)
44 (est)+26%
Calithera Biosciences was founded in 2010 and is headquartered in South San Francisco, US

Calithera Biosciences Office Locations

Calithera Biosciences has an office in South San Francisco
South San Francisco, US (HQ)
200 343 Oyster Point Blvd

Calithera Biosciences Metrics

Calithera Biosciences Market Value History

Calithera Biosciences Online Presence

Calithera Biosciences Company Life

You may also be interested in